title: Clinical features and treatment outcomes of angioimmunoblastic T-cell lymphoma.
abstract: The objective of this retrospective study was to investigate clinical features and treatment outcomes in patients with angioimmunoblastic T-cell lymphoma (AITL), data of which were collected over a 15-year period. Sixty-five patients diagnosed with AITL were included in the study. About half of the patients (46.2%) presented with poor performance status (ECOG > or = 2); 72.3% of patients belonged to high intermediate or high-risk of IPI and same proportion belonged to Class 2 of PIT (Prognostic index for PTCL-U), and most patients (95.4%) were diagnosed at an advanced stage. At diagnosis, 27 patients (41.5%) presented with malignant pleural effusion, and 22 patients (33.8%) had skin involvement. Most of the initial chemotherapy regimens were anthracycline-based (88.2%). Overall response rate to initial chemotherapy was 86.2% (64.7% of complete response, 21.5% of partial response). The median progression-free survival and overall survival of all patients was 7.1 months (95% CI, 2.8 - 11.4) and 15.1 months (95% CI, 6.7 - 23.5), respectively. Age, performance status, and PIT scores were predictive prognostic factors for survival. In conclusion, although AITLs showed a good response to the initial chemotherapy, their response durations were short; therefore, chemotherapy for AITL should be modified or intensified as in high-dose chemotherapy.
authors: Division of Hematology/Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
authors: Byeong-Bae
authors: BB
authors: Park
authors: Baek-Yeol
authors: BY
authors: Ryoo
authors: Jae H
authors: JH
authors: Lee
authors: Hyuck C
authors: HC
authors: Kwon
authors: Sung H
authors: SH
authors: Yang
authors: Hye J
authors: HJ
authors: Kang
authors: Hyo J
authors: HJ
authors: Kim
authors: Sung Y
authors: SY
authors: Oh
authors: Young H
authors: YH
authors: Ko
authors: Joo R
authors: JR
authors: Huh
authors: Seung S
authors: SS
authors: Lee
authors: Eun M
authors: EM
authors: Nam
authors: Keon W
authors: KW
authors: Park
authors: Jung H
authors: JH
authors: Kim
authors: Jung H
authors: JH
authors: Kang
authors: Soo M
authors: SM
authors: Bang
authors: Sarah
authors: S
authors: Park
authors: Kihyun
authors: K
authors: Kim
authors: Keunchil
authors: K
authors: Park
authors: Cheolwon
authors: C
authors: Suh
authors: Won S
authors: WS
authors: Kim
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018943:Anthracyclines / Q000494:pharmacology; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D016399:Lymphoma, T-Cell / Q000276:immunology* / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009389:Neovascularization, Pathologic; D011379:Prognosis; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D018943:Anthracyclines